How FDA Classifies Medical Devices: Class I, II, and III Explained

Medical device classification is the single most consequential determination you will make early in a product's regulatory lifecycle. Get it right, and you have a clear path to market. Get it wrong, and you may spend 12–18 months pursuing the wrong submission type — or launch a product that triggers an enforcement action. This guide explains how FDA's three-class system works, how to use the agency's own tools to find your device's classification, and what to do when the answer is genuinely ambiguous. --- ## 1. What Is Device Classification and Why It Controls Everything Under the Federal Food, Drug, and Cosmetic Act (FD&C Act), FDA assigns every medical device to one of three regulatory classes based on the **level of control necessary to provide reasonable assurance of safety and effectiveness**. The higher the risk a device poses to patients, the higher the class — and the more regulatory oversight FDA imposes before and after market entry. Classification is not merely an administrative label. It directly determines: * **Which premarket submission pathway applies** — 510(k), De Novo, or Premarket Approval (PMA) * **Whether premarket review by FDA is required at all** * **Which quality system regulations apply** under 21 CFR Part 820 (Quality System Regulation, now aligned with ISO 13485 through the Quality Management System Regulation effective February 2026) * **What postmarket surveillance obligations** you carry under 21 CFR Part 803 (MDR) and Part 822 The statutory basis for classification sits in Section 513 of the FD&C Act (21 U.S.C. § 360c). FDA has codified the resulting device classifications in 21 CFR Parts 862 through 892, organized by medical specialty panel. --- ## 2. The Three Classes: A Detailed Breakdown ### Class I — General Controls **Risk level:** Low **Premarket submission required:** Generally no (most are exempt) **Regulatory basis:** 21 CFR Parts 862–892, Subparts covering exempt devices Class I devices present minimal potential for harm and are subject only to **General Controls** — the baseline regulatory requirements that apply to every device regardless of class. General Controls include: * Registration and listing requirements (21 CFR Part 807) * Prohibited acts and adulteration/misbranding provisions (FD&C Act Sections 501–502) * Good Manufacturing Practice / Quality System requirements (21 CFR Part 820) * Medical Device Reporting for adverse events (21 CFR Part 803) * Labeling requirements (21 CFR Part 801) Approximately **47% of all device types are Class I**, and the vast majority are **510(k)-exempt**, meaning you do not need to submit a premarket notification before marketing the device. You still must register your establishment, list your device, and comply with applicable QSR requirements — exempt does not mean unregulated. **Examples from FDA's Product Classification Database:** | Device | Product Code | Regulation | Exempt? | |---|---|---|---| | Manual toothbrush | EFJ | 21 CFR 872.6390 | Yes | | Elastic bandage | FRO | 21 CFR 880.5075 | Yes | | Examination glove | FMF | 21 CFR 880.6250 | Yes | | Tongue depressor | KZH | 21 CFR 880.6230 | Yes | **Important nuance:** Some Class I devices are **not** 510(k)-exempt. Devices in this category still require premarket notification despite their low classification. Always verify exemption status against the specific product code, not just the class. --- ### Class II — Special Controls **Risk level:** Moderate **Premarket submission required:** Usually yes — 510(k) **Regulatory basis:** 21 CFR Parts 862–892, applicable product-specific sections Class II devices present greater risk than Class I and require **Special Controls** in addition to General Controls. Special Controls may include: * Performance standards (e.g., ISO or ASTM standards FDA has recognized) * Postmarket surveillance requirements * Patient registries * Special labeling requirements * Guidance documents specifying testing and performance criteria The workhorse submission pathway for Class II devices is the **510(k) premarket notification** (21 CFR Part 807, Subpart E). A 510(k) does not require you to prove absolute safety and effectiveness. Instead, you must demonstrate **substantial equivalence** — meaning your device has the same intended use and the same or equivalent technological characteristics as a legally marketed **predicate device** (a device already on the market that was cleared before May 28, 1976, or has itself been cleared through 510(k)). Approximately **43% of device types are Class II**. **Examples from FDA's Product Classification Database:** | Device | Product Code | Regulation | Pathway | |---|---|---|---| | Powered wheelchair | MYN | 21 CFR 890.3860 | 510(k) | | Infusion pump | KZG | 21 CFR 880.5860 | 510(k) | | Pulse oximeter | DQD | 21 CFR 870.2700 | 510(k) | | Digital mammography system | MRH | 21 CFR 892.1750 | 510(k) | | Continuous glucose monitor | OZO | 21 CFR 862.1345 | 510(k) / De Novo | The **De Novo** pathway (21 CFR Part 860, Subpart D) is also relevant here. When a device has no valid predicate — meaning no substantially equivalent device exists — but poses only low-to-moderate risk, a manufacturer may petition FDA through De Novo to establish a new Class I or Class II classification. A successful De Novo creates a new regulatory classification and, critically, makes that device available as a predicate for future 510(k)s. --- ### Class III — Premarket Approval **Risk level:** High **Premarket submission required:** Yes — PMA **Regulatory basis:** 21 CFR Part 814 Class III devices **support or sustain human life, are implanted, or present unreasonable risk of illness or injury** if they fail. They cannot be assured safe and effective through General or Special Controls alone. FDA requires a **Premarket Approval (PMA)** — the most rigorous premarket review pathway, functionally analogous to a new drug application. A PMA requires **valid scientific evidence**, typically including data from one or more well-controlled clinical investigations, to provide reasonable assurance of safety and effectiveness. FDA reviews manufacturing, device design, preclinical testing, and clinical data. The review clock is 180 days for an original PMA, though the real-world timeline including substantive FDA questions (Major Deficiency letters) routinely runs 12–36 months. Approximately **10% of device types are Class III**. **Examples from FDA's Product Classification Database:** | Device | Product Code | Regulation | Pathway | |---|---|---|---| | Implantable cardiac pacemaker | DSQ | 21 CFR 870.3610 | PMA | | Deep brain stimulator | GZB | 21 CFR 882.5860 | PMA | | Silicone gel-filled breast implant | FTR | 21 CFR 878.3530 | PMA | | Left ventricular assist device | DQM | 21 CFR 870.3545 | PMA | | Total artificial heart | DTB | 21 CFR 870.3925 | PMA | One important transitional category: some Class III devices currently on the market were cleared via 510(k) because FDA had not yet issued a final rule requiring PMAs for their device type. Under Section 515(b) of the FD&C Act, FDA can publish a **515(b) Order** requiring PMA submissions for these devices. If you are marketing a Class III device under a 510(k) clearance, monitor FDA's rulemaking activity in your product area carefully. --- ## 3. How to Determine Your Device's Class When the Answer Isn't Obvious For most established device types, the classification is already codified. Your job is to find it. For genuinely novel technologies, the analysis is more complex. ### Step 1: Search FDA's Product Classification Database The **FDA Product Classification Database** (accessible at accessdata.fda.gov/scripts/cdrh/cfdocs/cfPCD/classification.cfm) allows you to search by device name, product code, or CFR section. This is your first stop, not a secondary check. Use multiple search terms — the database indexes on regulation-specific language that may differ from your commercial naming conventions. ### Step 2: Review the Relevant CFR Part Once you have a product code candidate, read the corresponding CFR section in full. Pay particular attention to the **intended use** language. Classification hinges on what the device is intended to do, not solely what it is made of or how it works. ### Step 3: Review Cleared 510(k)s and Approved PMAs The **510(k) Premarket Notification Database** and **PMA Database** on FDA's website show how similar devices have been classified and reviewed. Reviewing 5–10 cleared predicate devices in your space provides concrete evidence of agency precedent and helps you build a predicate selection rationale. ### Step 4: Consider a 513(g) Request for Information If your device is novel or sits at the boundary between two classifications, you can submit a formal **513(g) Request for Designation** (under Section 513(g) of the FD&C Act) asking FDA to identify the applicable classification. FDA charges a user fee (currently $5,550 for FY2026 for a standard requester; check the current FDA user fee schedule). FDA responds within 60 days. This is not a binding clearance, but it provides documented agency feedback that can support your submission strategy and investor conversations. ### Step 5: Evaluate Combination Product Status If your device incorporates a drug, biologic, or software that independently meets the definition of a device, you may have a **combination product** governed by 21 CFR Part 3. The FDA Office of Combination Products (OCP) handles jurisdictional determinations. Classification and submission requirements shift substantially for combination products and require separate analysis. --- ## 4. Worked Example: Classifying a Novel Wearable Cardiac Arrhythmia Monitor **Scenario:** A startup has developed a wearable patch worn on the chest for 14 days that continuously records ECG data and uses an onboard algorithm to detect atrial fibrillation (AFib), flagging potential episodes for physician review. **Step 1 — Database search:** Searching "cardiac monitor" and "arrhythmia" in the Product Classification Database surfaces product code **DQD** (pulse oximeter, not applicable) and **MWI** — *Electrocardiograph* under 21 CFR 870.2340, Class II, 510(k)-required. A further search on "ambulatory ECG" returns **DQO** — *Ambulatory Electrocardiograph*, 21 CFR 870.2360, Class II. **Step 2 — Intended use scrutiny:** The device does more than record ECG; it includes an automated AFib detection algorithm. FDA has issued the guidance document *"Clinical Performance Assessment: Considerations for Computer-Assisted Detection Devices Applied to Radiology Images and Radiology Device Data in Premarket Notification Submissions"* (2020) and, more specifically for cardiac software, has cleared similar devices under product code **QCX** — *Software for Electrocardiograph Analysis*, 21 CFR 870.2345, Class II, 510(k)-required. **Step 3 — Software as a Medical Device:** The algorithm likely meets the definition of **Software as a Medical Device (SaMD)** under FDA's *"Policy for Device Software Functions and Mobile Medical Applications"* guidance (2019, updated 2022). FDA's risk-tiering for SaMD considers both the significance of the information provided and the state of the patient's condition. An AFib detection alert affecting treatment decisions in a potentially serious condition places this in a moderate-to-high SaMD risk tier — consistent with Class II or potentially Class III if the intended use shifts from "detect and refer" to "diagnose and direct treatment autonomously." **Outcome:** The startup should pursue a **510(k)** for the combined hardware/software device using a dual-predicate strategy: a cleared ambulatory ECG recorder as the hardware predicate, and a cleared ECG analysis software device as the software predicate. The submission will need to address analytical validation of the AFib detection algorithm, real-world performance data, and labeling that accurately reflects the intended use as a detection aid, not a standalone diagnostic. --- ## Key Takeaways * **Classification drives every downstream regulatory decision** — submission type, timeline, cost, and postmarket obligations all flow from whether your device is Class I, II, or III. Establish this determination before writing a single page of your design history file. * **"Exempt" does not mean "unregulated."** Class I exempt devices still require establishment registration, device listing, MDR reporting, and compliance with 21 CFR Part 820 quality system requirements in most cases. * **Intended use is the primary classification trigger**, not form factor or materials. A wearable patch that records ECG is classified differently from one that autonomously diagnoses and directs therapy — even if the hardware is identical. * **Use FDA's own databases first.** The Product Classification Database, 510(k) Database, and PMA Database are primary sources. A 513(g) Request for Designation provides documented FDA feedback when classification is genuinely ambiguous and is worth the investment for novel or high-stakes devices. * **Novel devices with no predicate are not automatically Class III.** The De Novo pathway exists precisely for low-to-moderate risk devices that lack a predicate, and a successful De Novo creates a new classification that benefits the entire industry as a future predicate source.